Given the limited role of anti-EGFR therapies in KRAS wild-type small bowel cancers or for right-sided colon cancers, anti-EGFR therapies for KRAS wild-type ampullary adenocarcinomas are not recommended [22]. Here, KRAS is linked to small intestine carcinoma.